



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Maria J. Pons
ma.pons.cas@gmail.com

SPECIALTY SECTION
This article was submitted to
Virus and Host,
a section of the journal
Frontiers in Cellular and
Infection Microbiology

RECEIVED 05 October 2022
ACCEPTED 13 October 2022
PUBLISHED 15 December 2022

CITATION
Palomino-Kobayashi LA, Ymaña B,
Ruiz J, Mayanga-Herrera A, Ugarte-
Gil MF and Pons MJ (2022)
Corrigendum: Zonulin, a marker of gut
permeability, is associated with
mortality in a cohort of hospitalised
peruvian COVID-19 patients.
Front. Cell. Infect. Microbiol.
12:1062174.
doi: 10.3389/fcimb.2022.1062174

COPYRIGHT
© 2022 Palomino-Kobayashi, Ymaña,
Ruiz, Mayanga-Herrera, Ugarte-Gil and
Pons. This is an open-access article
distributed under the terms of the
[Creative Commons Attribution License
\(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or
reproduction in other forums is
permitted, provided the original
author(s) and the copyright owner(s)
are credited and that the original
publication in this journal is cited, in
accordance with accepted academic
practice. No use, distribution or
reproduction is permitted which does
not comply with these terms.

Corrigendum: Zonulin, a marker of gut permeability, is associated with mortality in a cohort of hospitalised peruvian COVID-19 patients

Luciano A. Palomino-Kobayashi¹, Barbara Ymaña¹,
Joaquim Ruiz¹, Ana Mayanga-Herrera²,
Manuel F. Ugarte-Gil^{3,4} and Maria J. Pons^{1*}

¹Grupo Enfermedades Infecciosas Emergentes, Universidad Científica del Sur, Lima, Peru,

²Laboratorio de Cultivo Celular e Inmunología, Universidad Científica del Sur, Lima, Peru, ³Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru, ⁴Hospital Nacional Guillermo Almenara Irigoyen, EsSalud, Lima, Peru

KEYWORDS

microbial translocation, zonulin, COVID-19, biomarker, ELISA, Peru

A Corrigendum on

Zonulin, a marker of gut permeability, is associated with mortality in a cohort of hospitalised peruvian COVID-19 patients.

By Palomino-Kobayashi LA, Ymaña B, Ruiz J, Mayanga-Herrera A, Ugarte-Gil MF and Pons MJ (2022) *Front. Cell. Infect. Microbiol.* 12:1000291. doi: 10.3389/fcimb.2022.1000291

In the published article, there was a mistake in the Affiliations. Author Maria J Pons was affiliated with Affiliation 4 rather than Affiliation 1. The correct affiliations appear below. The authors apologize for this mistake.

Version of published affiliations:

Luciano A Palomino-Kobayashi 1, Barbara Ymaña 1, Joaquim Ruiz 1, Ana Mayanga-Herrera 2, Manuel F Ugarte-Gil 3 4, Maria J Pons 4

1Grupo Enfermedades Infecciosas Emergentes, Universidad Científica del Sur, Lima, Peru.

2Laboratorio de Cultivo Celular e Inmunología, Universidad Científica del Sur, Lima, Peru.

3Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru.

4Hospital Nacional Guillermo Almenara Irigoyen, EsSalud, Lima, Peru.

Correct version of the affiliation:

Luciano A Palomino-Kobayashi 1, Barbara Ymaña 1, Joaquim Ruiz 1, Ana Mayanga-Herrera 2, Manuel F Ugarte-Gil 3 4, Maria J Pons 1

1Grupo Enfermedades Infecciosas Emergentes. Universidad Científica del Sur, Lima, Peru.

2Laboratorio de Cultivo Celular e Inmunología, Universidad Científica del Sur, Lima, Peru.

3Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru.

4Hospital Nacional Guillermo Almenara Irigoyen, EsSalud, Lima, Peru.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.